






# Calciophylaxis

SKC In-service April 2015

# Normal Artery




# Atherosclerotic Vascular Disease




# Vascular Disease of ESRD




# Shear Stress




## Healthy Artery




## 1. Endothelial dysfunction



## 2. Vascular remodeling



## 3. Plexiform lesion & In situ Thrombosis



# Why do arteries calcify in ESRD?

- High phosphorus → Ca/Phos deposition in tissues
- Uremic toxins
- Imbalance of vascular regulators
- Hypertension
- Inflammation
- ?Dysregulation of coagulation system

# What is Calciphylaxis?

- Calcific uremic arteriopathy
  - Systemic medial calcification of the arteries, tunica media. Unlike other forms of vascular calcifications (e.g., intimal, medial, valvular), calciphylaxis is characterised also by small vessel mural calcification with or without endovascular fibrosis, extravascular calcification and vascular thrombosis, leading to tissue ischemia (including skin ischemia and, hence, skin necrosis).
- Incidence in dialysis patients < 1% per year
- Mortality rate from 40-80% at 1 year




# Classic pictures of calciphylaxis



Presentation can be subtle / not classic...





100  $\mu$ m



200 um



# Risk Factors For Calciphylaxis

**Table 2. Case-Control Studies Identified the Following Parameters and Clinical Conditions as Risk Factors for Calciphylaxis**

---

Obesity, liver disease, and systemic corticosteroid use<sup>4</sup>

Low albumin levels and previous warfarin application<sup>8</sup>

High serum phosphate, high calcium-phosphate product, previous calcium, and vitamin D therapy<sup>9</sup>

Female sex, low albumin levels, high alkaline phosphatase level, and high serum phosphorus levels<sup>10</sup>

Low albumin level, previous calcitriol therapy, not using statins, high serum calcium levels, and previous warfarin use<sup>11</sup>

---

**Table 3.** Summary of treatment options in calciphylaxis

Intensification of dialysis therapy

- Increasing dialysis length, frequency (weekly dialysis dose)
- Switch from hemodialysis to hemodiafiltration
- Switch from peritoneal dialysis to hemodialysis/  
hemodiafiltration

Reduction of calcium supply and calcium intake

- Switch to calcium-free or calcium-reduced phosphate binders (such as sevelamer or lanthanum, magnesium-based, or iron-based binders)
- Reduction of active vitamin D dose

Stop vitamin K antagonist treatment and start vitamin K supplementation instead

- Use alternative long-term anticoagulation therapy such as intravenous heparin or low-molecular-weight heparin in a reduced dose

Therapy of hyperparathyroidism without induction of adynamic bone disease


- Application of cinacalcet
- Parathyroidectomy
- Optimal CKD-MBD therapy including native vitamin D supplementation (ergocalciferol, cholecalciferol)

Reduction of calcification pressure (Table 4)

Improve oxygen supply (eg via hyperbaric O<sub>2</sub> therapy)

Supportive therapy

- Wound management
- Treat local and systemic infection, regular wound swabs
- Pain management according to World Health Organization standards
- Limb amputation in uncontrolled clinical settings
- Psychological care for patients and family




# Treatment Options

**Table 4.** Specific Interventions in CUA Patients Aimed at New Balance Between Procalcifying and Anticalcifying Factors

Sodium-thiosulfate (STS)

Bisphosphonates

Parathyroidectomy/cinacalcet



Meet Mr. Bates, our perfect patient. He controls his fluid levels by not drinking and his potassium, cholesterol and phosphates by not eating.